The estimated Net Worth of Victoria L. Brown is at least $1.08 Milhão dollars as of 17 June 2022. Ms. Brown owns over 2,698 units of Apellis Pharmaceuticals Inc stock worth over $958,003 and over the last 4 years she sold APLS stock worth over $121,410. In addition, she makes $0 as Senior Vice President e Program Team Lead – Systemic Chronic at Apellis Pharmaceuticals Inc.
Victoria has made over 2 trades of the Apellis Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 2,698 units of APLS stock worth $121,410 on 17 June 2022.
The largest trade she's ever made was exercising 12,000 units of Apellis Pharmaceuticals Inc stock on 7 October 2020 worth over $227,760. On average, Victoria trades about 1,131 units every 48 days since 2020. As of 17 June 2022 she still owns at least 24,974 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Ms. Brown stock trades at the bottom of the page.
Victoria Brown serves as Senior Vice President, Program Team Lead – Systemic Chronic of the Company. Prior to joining our company, from December 2009 to January 2019, Ms. Brown held a variety of executive roles at Biogen Inc, or Biogen, including Senior Director, Portfolio and Pipeline Brand Lead from August 2017 to January 2019, Director, US Brand Lead from September 2015 to July 2017, and Director, Global Brand Lead, from September 2014 to September 2015. Before Biogen, Ms. Brown spent 10 years at Janssen Pharmaceuticals holding numerous leadership positions with increasing levels of scope and responsibility. Ms. Brown has a B.S. (Hons) in health sciences from the University of Aberdeen
Victoria Brown is 41, she's been the Senior Vice President e Program Team Lead – Systemic Chronic of Apellis Pharmaceuticals Inc since 2020. There are 23 older and no younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
Victoria's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois, ePascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: